OPTOCIRCUI

Opto Circuits (India) Limited has informed the Exchange regarding 'Eurocor Tech GmbH launches innovative new Sirolimus Coated Stent Eurolimus '.

Opto Circuits (India) Limited has informed the Exchange regarding 'Appointment of Compliance Officer'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Disclosure under regulation 30 of SEBI (LODR) Regulation 2015.'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Book Closure & E-voing details'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligation and DisclosureRequirement) Regulations, 2015- Resignation of Independent Director, convening the 28th AGM and closure of Register of Members and Share Transfer Books'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Update'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Updates'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Updates'.

Opto Circuits (India) Limited has informed the Exchange regarding ''.

Opto Circuits (India) Limited has informed the Exchange regarding 'Change in Contact Details of Company Secretary & Compliance Officer of the Company.'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Change of name of the Share Transfer Agent of the Company from "Karvy Fintech Private Limited" to "KFIN Technologies Private Limited"'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Appointment of Compliance Officer'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Recall / Disposal of Winding up order by Honourable High Court of Karnataka.'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Approval of Proposal for Settlement with Banks'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Undertaking-Initial Disclosure-Identified as Large Corporate '.

Opto Circuits (India) Limited has informed the Exchange regarding 'Regulation 30(6) of SEBI (LODR) Regulations 2015 - Election of Chairman'.

Opto Circuits (India) Limited has informed the Exchange regarding 'Approval of Proposal for One Time Settlement "OTS" with YES BANK LTD'.

Opto Circuits (India) Limited has informed the Exchange regarding Investors update letter issued by the Company regarding progress and significant events.

Opto Circuits (India) Limited has informed the Exchange that, in terms of the approval under Companies Act, 2013, the Company has obtained approval from the Office of the Registrar of Companies (ROC), Karnataka, an extension of time for holding Annual General Meeting (AGM) of the Company, for the Financial Year ended March 31, 2015.Accordingly the Company will hold the Annual General Meeting on or before December 31, 2015.

Opto Circuits (India) Limited has informed the Exchange that "Opto Cardiac Care Limited, a subsidiary of Opto Circuits (India) Limited has been successful in getting back Criticare Systems Inc USA, which was placed in Chapter 128 (Bankruptcy Court) by Aurora Capital, who bought the loan from our lender DBS Bank Limited. Criticare Systems Inc, is now back as part of the Opto Group of Companies".

Opto Circuits (India) Limited has informed the Exchange that one of the Company's subsidiary company, viz Cardiac Science Corporation, USA, has filed voluntary petition under Chapter 11 of the US Bankruptcy Code to Facilitate Debt Restructuring in US Bankruptcy Courts in the Western District of Wisconsin on October 20, 2015.The above action is initiated by the secured lenders to the Company for such filing and the management of Opto Circuits (India) Limited is taking effective legal recourse required in this regard.

Opto Circuits (India) Limited has informed the Exchange that one of the step down overseas subsidiary company, viz Cardiac Science Corporation, USA, has filed voluntary petition under Chapter 11 of the US Bankruptcy Codeto Facilitate Debt Restructuring in US Bankruptcy Courts in the Western District of Wisconsin on October 20, 2015.

Opto Circuits (India) Limited has informed the Exchange that the in view of current market conditions, the GDR issue of the company has been deferred till further notice.

Opto Circuits (India) Limited has submitted to the Exchange vide its letter dated May 31, 2013, a copy of Revised Audited Financial Results of Company for the quarter and year ended 31st March 2013.

Opto Circuits (India) Limited has informed the Exchange vide letter dated February 05, 2013 that none of the Promoters shares have ever been pledged.

Opto Circuits (India) Limited has informed the Exchange that Mr. Srinatha A N has been transferred to Opto Circuits (India) Limited ('OCIL') from Opto Eurocor Healthcare Limited ( subsidiary of OCIL ) as Company Secretary and Compliance Officer in place of Mr. K.V. Ganesh.

Opto Circuits (India) Limited has informed the Exchange that the Company has appointed CRISIL on July 04, 2012 to rate the credit facilities of the Company.

Opto Circuits (India) Limited has informed the Exchange that OPTO EUROCOR HEALTHCARE LTD., wholly owned subsidiary of the Company proposes to raise upto Rs.1000.00 crores through Initial Public Offering.

Opto Circuits (India) Limited has informed the Exchange that the Company has been featured in Forbes Asia's 200 'Best Under a Billion' List, 2011. This is the third time the Company have made it to this list, the last two times being 2008 and 2009.

Opto Circuits (India) Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 22, 2011 has approved to increase the Foreign Financial Institutions (FII) limit of existing 40% to 49% in the company's paid up capital subject to the approval of the shareholders.

Opto Circuits (India) Limited has informed the Exchange that the Company, for the purpose of cost effectiveness and operational efficiency, has taken restructuring initiative and transferred the investments of three of its US Subsidiaries, Cardiac Science Corporation, Criticare Systems Inc., and Unetixs Vascular Inc., into Opto Cardiac Care Limited, a Wholly Owned Subsidiary of Opto Circuits (India) Limited. Further, the Company has also transferred the investments of its subsidiaries, Eurocor Gmbh, and N.S.Remedies Private Limited, into Opto Eurocor Healthcare Limited, a Wholly Owned Subsidia

Opto Circuits (India) Limited has informed the Exchange that Opto Circuits (India) Ltd.'s subsidiary Cardiac Science Corporation has received regulatory clearance from the Japan Ministry of Health, Labor, and Welfare to market its Powerheart G3 Automated External Defibrillators (AED) in Japan.

Opto Circuits (India) Limited has informed the Exchange that OPTO CARDIAC CARE LIMITED Bangalore has become wholly owned subsidiary of the company, after complying with all the legal formalities.

Opto Circuits (India) Limited has informed the Exchange that Company's wholly owned subsidiary i.e. Altron Industries Pvt Limited's name has changed to OPTO EUROCOR HEALTHCARE PVT LTD., The company has complied with all legal and statutory formalities.

Opto Circuits (India) Limited has informed the Exchange that "the company has successfully acquired 76% of outstanding common stock of Cardiac Science Corporation US (Nasdaq:CSCX). The company plans to exercise its top-up option under the terms of the merger agreement. The merger is expected to occur in the next few days. Following the merger, Cardiac Science will become a wholly-owned subsidiary of Opto Circuits (India) Limited."

Opto Circuits (India) Limited has informed the Exchange vide its letter dated April 09, 2010 that "The Board of Directors of the company at their meeting held on this day allotted 15,00,000 Convertible Share Warrants to Mr. Gautam G Gumnani which was kept pending for Foreign Investment Promotion Board's (FIPB) approval. The Company has now received FIPB approval vide Letter No.31(2010)/166(2009) dated 6th April 2010, issued by the Government of India, Ministry of Finance, Department of Economic Affairs, FIPB".

Opto Circuits (India) Limited has informed the Exchange vide its letter dated March 30, 2010 that "Based on the application filed by the company, the Government of India through FIPB has approved the issue and allotment of 15,00,000 convertible share warrants amounting to Rs. 31.50 Crores. However in the official website of FIPB the amount of inflow is mentioned as Rs. 376.27 crores. The company has communicated to FIPB to make necessary amendments."

Opto Circuits (India) Limited has informed the Exchange that Company's wholly - owned US-based subsidiary, Criticare Systems Inc. (CSI), has forged a strategic multi-year OEM (Original Equipment Manufacturing) contract with another US company to privately label its anesthesia monitor for the signed partner. The agreement leverages CSI's unique anesthesia gas monitoring technology in applications that involve the calibration and maintenance of anesthesia equipment in some of the leading hospitals in the United States. CSI is an international medical device company that develops, manufactures an

Opto Circuits (India) Limited has informed the Exchange that: "The company has received US FDA approval on a next-generation pulse oximeter (SpO2) module, Sequel (TM) developed by its Waukesha-based subsidiary- Criticare Systems Inc. (CSI). The approval enables immediate integration of the module into CSI monitors and marketing and sale of the product to OEM manufacturers across the globe.Sequel (TM) is a miniaturised, motion-tolerant and a more sensitive SpO2 module that is designed to power new generation vital signs monitors and other patient monitors for the entire CSI range of products. T

Opto Circuits (India) Limited has informed the Exchange that: "California-based Mediaid Inc., the subsidiary Company and the International Marketing arm of the Company has received Brazilian FDA agency- Agencia Nacional de Vigilancia Sanitaria (ANVISA)- approval for marketing and sale of the Mediaid brand of US FDA-approved Pulse Oximetry (SPO2) products (Patient Monitors & Sensors) in the Country and surrounding geographies".

Opto Circuits (India) Limited has informed the Exchange that Maxcor Lifesience, Inc., the newly incorporated subsidiary of the Company (OCI), entered into a strategic cooperation agreement with Micell Technologies, Inc., based in Raleigh, North Carolina, U.S.A. Maxcor and Micell will co-operate in developing and commercializing leading edge Rapamycin (Sirolimus) - based Drug Eluting Stents (DES) and Drug Eluting Balloons (DEB) which will complement OCI's present range of successful paclitaxel-based drug-device combination products. Offering products with both compounds will enable OCI to maxim

Opto Circuits (India) Limited has informed the Exchange that "The management of the company has evaluated the proposed acquisition of European company while the underlying the business is found to be very valuable and synergistically complementary, the demanded price is not justifiable from the economic value prospective. So the company is not considering the proposed European acquisition".

Opto Circuits (India) Limited has informed the Exchange that " Criticare System Inc, USA the company's wholly owned subsidiary has launched its two new series of patient monitors eQuality and Ncompass which were developed by company's in-house Research and Development team". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OPTOCIR_UPDATE_25092008.zip target=NEW> For more details click here.</a>

Opto Circuits (India) Limited has informed the Exchange that Eurocor GmbH the Company's wholly owned subsidiary has received registration for its Drug Eluting Balloon, Dior in India. The commercial release of Dior will commence after fulfilling the guidelines provided by Drug Control General of India (DCGI). The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OPTO_UPDATES_24092008.zip target=NEW> For more details click here.</a>

Opto Circuits (India) Limited has informed the Exchange that "Mediaid Inc. wholly owned subsidiary of Opto Circuits (India) Limited received approval from the United States Food and Drug Administration (FDA) for key vital sign monitoring products. The Model 900 and Model 960 Vital Sign Monitors are the first Opto bed-side monitors to receive the crucial approval for marketing in the United States. Receiving approval for these high-end products opens up the U.S. hospital market. The Model 900 and 960 devices monitor Blood-oxygen, Blood-pressure and Temperature for a complete and quick assessmen